MATINAS BIOPHARMA HOLDINGS, INC. Payments of Stock Issuance Costs
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Payments of Stock Issuance Costs of $29.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-03-31
- MATINAS BIOPHARMA HOLDINGS, INC. payments of stock issuance costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. payments of stock issuance costs for the quarter ending 2025-06-30 was $27.00K, a 96.67% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. payments of stock issuance costs for the quarter ending 2025-03-31 was $2.00K, a 0.00% change year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. payments of stock issuance costs for the quarter ending 2024-12-31 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. payments of stock issuance costs for fiscal 2024 was $877.00K.
- MATINAS BIOPHARMA HOLDINGS, INC. payments of stock issuance costs for fiscal 2020 was $3.30M, a 42.44% increase from fiscal 2019.
- MATINAS BIOPHARMA HOLDINGS, INC. payments of stock issuance costs for fiscal 2019 was $2.32M.
- MATINAS BIOPHARMA HOLDINGS, INC. payments of stock issuance costs for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
| Period end | Payments of Stock Issuance Costs 2 month | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month | Payments of Stock Issuance Costs 32 month |
|---|---|---|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $27.00K derived: sum of 2 quarters · filed 2025-11-10 | $29.00K 10-Q · filed 2025-11-10 | $29.00K derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2025-06-30 | $27.00K 10-Q · filed 2025-08-14 | $29.00K 10-Q · filed 2025-08-14 | $29.00K derived: sum of 3 quarters · filed 2026-03-31 | $94.00K derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2025-03-31 | $2.00K 10-Q · filed 2025-05-15 | $2.00K derived: sum of 2 quarters · filed 2026-03-31 | $67.00K derived: sum of 3 quarters · filed 2026-03-31 | $877.00K derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $65.00K derived: sum of 2 quarters · filed 2026-03-31 | $875.00K derived: sum of 3 quarters · filed 2026-03-31 | $877.00K 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $65.00K 10-Q · filed 2025-11-10 | $875.00K derived: sum of 2 quarters · filed 2025-11-10 | $877.00K 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $810.00K 10-Q · filed 2025-08-14 | $812.00K 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | $2.00K 10-Q · filed 2025-05-15 | |||||
| 2020-12-31 | $3.30M 10-K · filed 2021-03-29 | |||||
| 2019-12-31 | $2.32M 10-K · filed 2021-03-29 | |||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $0.00 10-K · filed 2017-03-31 | ||||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-14 | |||||
| 2015-12-31 | -$285.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $7.66K derived: sum of 2 quarters · filed 2017-03-31 | $830.73K derived: sum of 3 quarters · filed 2017-03-31 | $1.49M 10-K · filed 2017-03-31 | ||
| 2015-09-30 | $7.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $831.01K derived: sum of 2 quarters · filed 2016-11-14 | $1.49M 10-Q · filed 2016-11-14 | $1.49M derived: sum of 4 quarters · filed 2016-11-14 | ||
| 2015-06-30 | $823.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $1.48M 10-Q · filed 2015-08-13 | $1.48M derived: sum of 3 quarters · filed 2015-08-13 | $1.48M derived: sum of 4 quarters · filed 2015-11-10 | ||
| 2015-03-31 | $654.77K 10-Q · filed 2015-05-15 | $654.77K derived: sum of 2 quarters · filed 2015-05-15 | $654.77K derived: sum of 3 quarters · filed 2015-11-10 | $654.77K derived: sum of 4 quarters · filed 2015-11-10 | ||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $0.00 derived: sum of 2 quarters · filed 2015-11-10 | $0.00 derived: sum of 3 quarters · filed 2015-11-10 | $0.00 10-K · filed 2015-03-31 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $0.00 derived: sum of 2 quarters · filed 2015-11-10 | $0.00 10-Q · filed 2015-11-10 | -$2.00 derived: sum of 4 quarters · filed 2015-11-10 | ||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $0.00 10-Q · filed 2015-08-13 | -$2.00 derived: sum of 3 quarters · filed 2015-08-13 | |||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-15 | -$2.00 derived: sum of 2 quarters · filed 2015-05-15 | $2.38M 10-Q · filed 2014-06-06 | |||
| 2013-12-31 | -$2.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $2.38M 10-K · filed 2015-03-31 | ||||
| 2013-09-30 | $2.38M 10-Q · filed 2014-11-14 | |||||
| 2013-08-31 | $2.40M 10-K · filed 2015-03-31 | |||||
| 2013-03-31 | $0.00 10-Q · filed 2014-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |